opaganib
Small moleculeexperimental
Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS). It is under development as a potential treatment agent for several different kinds of cancer. Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha. — Wikipedia
Clinical trial activity
10 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01488513)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 2
- Cholangiocarcinoma · Phase 2
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2/Phase 3
- Klatskin Tumor · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Respiratory Tract Infections · Phase 2/Phase 3
- Sarcoma, Kaposi · Phase 1/Phase 2
Mechanism of action
- Sphingosine kinase 2INHIBITOR
SPHK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOpaganib ↗
Also known as
- 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
- 4-pyridinylmethyl-3-(4-chlorophenyl) adamantane carboxamide
- abc294640
- abc294640
- abc294640
- abc 294640
- abc-294640
- abc-294640
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04502069 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2020 | RedHill Biopharma |
| NCT04467840 | Phase 2/Phase 3 (Phase 3) | Aug 21, 2020 | RedHill Biopharma |
| NCT04414618 | Phase 2 | May 29, 2020 | RedHill Biopharma |
| NCT04207255 | Phase 2 | Feb 1, 2020 | Medical University of South Carolina, National Cancer Institute (NCI) |
| NCT03377179 | Phase 2 | Mar 7, 2018 | Mayo Clinic, RedHill Biopharma |
| NCT02939807 | Phase 2 | Dec 14, 2016 | Apogee Biotechnology Corporation, Medical University of South Carolina, National Cancer Institute (NCI), RedHill Biopharma |
| NCT02757326 | Phase 1/Phase 2 (Phase 2) | Dec 13, 2016 | Apogee Biotechnology Corporation, Duke University, National Cancer Institute (NCI), RedHill Biopharma |
| NCT02229981 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2014 | Apogee Biotechnology Corporation, Louisiana State University, RedHill Biopharma |
| NCT01488513 | Phase 1 | Aug 1, 2011 | Apogee Biotechnology Corporation, Food and Drug Administration, Medical University of South Carolina, National Cancer Institute (NCI), RedHill Biopharma |
| NCT03414489 | N/A | — | RedHill Biopharma |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RedHill Biopharma | For profit | 9 | 9 | 4 | 2011 |
| Apogee Biotechnology Corporation | For profit | 4 | 0 | 2 | 2011 |
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2011 |
| Medical University of South Carolina | Academic/Hospital | 3 | 1 | 2 | 2011 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2011 |
| Louisiana State University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2018 |
8 organizations
Page 1 / 1